Indeed, multiphosphomimetic analogues of MAP65–1 have reduced microtubule-binding ability. Hyperphosphorylated AtMAP65–1 was observed during prophase and metaphase, a period of inhibition of MAP65–1 activity (Smertenko et al., 2006).
Indeed, multiphosphomimetic analogues of MAP65–1 have reduced microtubule-binding ability. Hyperphosphorylated AtMAP65–1 was observed during prophase and metaphase, a period of inhibition of MAP65–1 activity (Smertenko et al., 2006).